Can analysts adopt a bullish outlook for Merck & Co., Inc. (NYSE:MRK)?

April 26, 2018 - By Richard Conner

Merck & Co., Inc. (NYSE:MRK) LogoInvestors sentiment decreased to 0.94 in Q4 2017. Its down 0.12, from 1.06 in 2017Q3. It dived, as 94 investors sold Merck & Co., Inc. shares while 631 reduced holdings. 123 funds opened positions while 558 raised stakes. 1.93 billion shares or 1.34% less from 1.96 billion shares in 2017Q3 were reported.
Wetherby Asset Mgmt Incorporated invested in 0.71% or 91,226 shares. Mackenzie stated it has 0.81% in Merck & Co., Inc. (NYSE:MRK). Cipher Cap Ltd Partnership reported 53,543 shares. Triangle Wealth Mngmt stated it has 0.47% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Glovista Invs Ltd Co has 6,399 shares. Liberty Mutual Group Inc Asset Management invested in 109,013 shares or 0.18% of the stock. Management Professionals invested 0.03% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Private Wealth Advsr holds 39,141 shares. Pettee Invsts holds 1.3% or 38,059 shares in its portfolio. Violich Cap Mngmt holds 0.74% of its portfolio in Merck & Co., Inc. (NYSE:MRK) for 51,681 shares. Condor Cap Mgmt has invested 0.05% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Regent Inv Mngmt Limited Liability Company stated it has 42,495 shares or 0.78% of all its holdings. Forte Capital Ltd Limited Liability Company Adv owns 23,802 shares for 0.4% of their portfolio. Chevy Chase Holdings holds 0.72% in Merck & Co., Inc. (NYSE:MRK) or 2.99 million shares. Cliftonlarsonallen Wealth Advsrs Lc reported 29,374 shares stake.

Merck & Co., Inc. (NYSE:MRK) Ratings Coverage

Among 17 analysts covering Merck \u0026 Co (NYSE:MRK), 14 have Buy rating, 0 Sell and 3 Hold. Therefore 82% are positive. Merck \u0026 Co had 32 analyst reports since October 30, 2017 according to SRatingsIntel. As per Thursday, April 5, the company rating was upgraded by Barclays Capital. Barclays Capital downgraded Merck & Co., Inc. (NYSE:MRK) on Monday, October 30 to “Equal-Weight” rating. Bank of America maintained the shares of MRK in report on Tuesday, April 17 with “Buy” rating. The firm earned “Outperform” rating on Wednesday, February 14 by Credit Suisse. The company was upgraded on Monday, March 12 by Leerink Swann. On Tuesday, January 16 the stock rating was maintained by Jefferies with “Hold”. Jefferies maintained it with “Hold” rating and $5600 target in Friday, April 13 report. The firm earned “Equal-Weight” rating on Monday, October 30 by Morgan Stanley. The stock of Merck & Co., Inc. (NYSE:MRK) has “Buy” rating given on Wednesday, November 15 by Bernstein. Credit Suisse maintained the stock with “Outperform” rating in Monday, February 5 report. Below is a list of Merck & Co., Inc. (NYSE:MRK) latest ratings and price target changes.

23/04/2018 Broker: Goldman Sachs Rating: Buy New Target: $73.0000 Upgrade
20/04/2018 Broker: Cowen & Co Rating: Hold New Target: $67.0000 Maintain
17/04/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $68 New Target: $70 Maintain
17/04/2018 Broker: Guggenheim Rating: Buy New Target: $72.0000 Maintain
17/04/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Overweight Old Target: $63 Upgrade
13/04/2018 Broker: Jefferies Rating: Hold New Target: $56.0000 Maintain
05/04/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Overweight Upgrade
23/03/2018 Broker: Jefferies Rating: Hold New Target: $55.0000 Maintain
12/03/2018 Broker: Leerink Swann Rating: Buy New Target: $66.0 Upgrade
26/02/2018 Broker: Jefferies Rating: Hold New Target: $56.0 Maintain

The stock decreased 0.05% or $0.03 during the last trading session, reaching $59.6. About 8.12M shares traded. Merck & Co., Inc. (NYSE:MRK) has declined 14.94% since April 26, 2017 and is downtrending. It has underperformed by 26.49% the S&P500.

Merck & Co., Inc. provides healthcare solutions worldwide. The company has market cap of $160.49 billion. It operates in four divisions: Pharmaceutical, Animal Health, Healthcare Services, and Alliances divisions. It has a 68.51 P/E ratio. The firm offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal and intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Merck & Co., Inc. (NYSE:MRK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.